Rodríguez-Tanta L Yesenia, Garavito Farro Héctor, Freitas Leal Lisiane, Salas Maribel, Elseviers Monique M, Lopes Luciane Cruz
Institute for the Evaluation of Health Technologies and Research, Social Security of Health, Lima, Peru.
Ministry of Health of Peru, Lima, Peru.
Front Pharmacol. 2023 Jan 17;13:1047946. doi: 10.3389/fphar.2022.1047946. eCollection 2022.
Drug utilization research (DUR) is used to provide evidence-based data to inform policies and make decisions. The aim of this study was to map and describe available data sources for drug utilization research in Peru. We performed a search of data sources providing information on medication use on the website of governmental organizations. We also conducted a literature review using PubMed, LILACs, and BVS. Independently, researchers screened eligible data sources. Data characterization included accessibility, coverage data provider, type of data sources, and setting. We performed a descriptive analysis. We identified seven data sources, CENAFyT, ICI, IDI (SISMED), and ENSUSALUD from MINSA, and CRI-ESSALUD, SGSS/ESSI, and ENSSA from ESSALUD. These presented information on adverse drug reactions ( = 2), drug consumption, and distribution ( = 2), prescription and drug dispensing ( = 1), and surveys addressed to medication users ( = 2). ENSUSALUD was the only data source publicly available. VIGIFLOW and ENSUSALUD have a national granularity from the public and private sectors. The setting of the data sources was both hospital and ambulatory care. Two data sources have individual-level data on adverse drug reactions and one on prescriptions. Four studies on drug utilization research in Peru were derived from ENSUSALUD. In Peru, few data sources are available for drug utilization research. There is an increased need to monitor medications for decision-making purposes. Local and international initiatives and partnerships of the government with academic institutions and the private sector might be a good strategy to increase the transparency of health data and for supporting decision-making using drug utilization research.
药物利用研究（DUR）用于提供循证数据，为政策制定和决策提供依据。本研究的目的是梳理和描述秘鲁药物利用研究的可用数据源。我们在政府组织网站上搜索了提供用药信息的数据源。我们还使用PubMed、LILACs和BVS进行了文献综述。研究人员独立筛选符合条件的数据源。数据特征包括可及性、覆盖范围、数据提供者、数据源类型和背景。我们进行了描述性分析。我们确定了七个数据源，即来自卫生部的CENAFyT、ICI、IDI（SISMED）和ENSUSALUD，以及来自社会保障局的CRI-ESSALUD、SGSS/ESSI和ENSSA。这些数据源提供了关于药物不良反应（=2）、药物消费和分配（=2）、处方和药物配给（=1）以及针对用药者的调查（=2）的信息。ENSUSALUD是唯一公开可用的数据源。VIGIFLOW和ENSUSALUD具有来自公共和私营部门的全国粒度数据。数据源的背景包括医院和门诊护理。两个数据源有关于药物不良反应的个体层面数据，一个有关于处方的个体层面数据。秘鲁四项关于药物利用研究的研究来自ENSUSALUD。在秘鲁，可用于药物利用研究的数据源很少。为了决策目的，监测药物的需求日益增加。政府与学术机构和私营部门的地方和国际倡议及伙伴关系可能是提高卫生数据透明度和支持利用药物利用研究进行决策的良好策略。
